Article
[Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer].
Gan to kagaku ryoho. Cancer & chemotherapy - 1 Aug 2011
Asai Hiroaki, Shinozaki Eiji, Nozaki Akira, Watanabe Toshiyasu, Suenaga Mitsukuni, Matuzaka Satoshi, Chin Keisho, Mizunuma Nobuyuki, Yasukawa Masaki, Hatake Kiyohiko
Abstract excerpt
Mutation of the KRAS gene in patients with metastatic colorectal cancer(mCRC)has been established as a predictive marker of poor response to anti-EGFR cetuximab. The Japanese Society of Medical Oncology recommends that the KRAS mutation status at codon 12 and codon 13 should be genotyped by direct-sequencing or allele-specific PCR. In this study, we tested the point mutation of codon 12 and 13 in the KRAS gene by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.